MTK 458
Alternative Names: MTK-458Latest Information Update: 09 Oct 2023
At a glance
- Originator Mitokinin
- Developer AbbVie
- Class Antidementias; Antiparkinsonians; Small molecules
- Mechanism of Action Protein-serine-threonine kinase stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Alzheimer's disease; Huntington's disease; Mitochondrial disorders
- No development reported Parkinson's disease